MODAFINIL | A207196 | APPCO PHARMA LLC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Appco Pharma LLC FDA-2026-P-6706 · 6 docket documents Appco Pharma LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting FDA permission to submit an Abbreviated New Drug Application for Modafinil Tablets in 50 mg and 150 mg strengths, which differ from the Reference Listed Drug Provigil (ap | Suitability | 2026-06-11 | Open | Appco Pharma LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.3556
per ea
Lowest NADAC/Unit
$0.2415
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 23155060503MODAFINIL 200 MG TABLET | $0.3556 | EA | Generic | — | 2026-06-17 |
| 23155060509MODAFINIL 200 MG TABLET | $0.3556 | EA | Generic | — | 2026-06-17 |
| 23155086203MODAFINIL 200 MG TABLET | $0.3556 | EA | Generic | — | 2026-06-17 |
| 23155086209MODAFINIL 200 MG TABLET | $0.3556 | EA | Generic | — | 2026-06-17 |
| 23155060403MODAFINIL 100 MG TABLET | $0.2415 | EA | Generic | — | 2026-06-17 |
| 23155060409MODAFINIL 100 MG TABLET | $0.2415 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.